The FirstTake Podcast – The FDA faces up to a tricky ALS regulatory decision, Roche’s TIGIT setback and more…
Update: 2022-03-31
Description
On this week’s episode Virginia Li discusses the closely watched FDA AdCom meeting for Amylyx’s ALS therapy AMX0035, which saw experts vote narrowly against Amylyx having shown sufficient efficacy for the drug from a single clinical study. Simon King looks at two major clinical data announcements – for Almirall and Eli Lilly’s atopic dermatitis drug lebrikizumab and Roche’s potential cancer therapy tiragolumab. And FirstWord HealthTech’s Tina Tan highlights some notable trends in health tech venture capitalist investments during the first quarter of 2022, ahead of an exclusive live event for FirstWord HealthTech PLUS subscribers next week where she will provide a more comprehensive overview of VC activity.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
